1. Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

3. Patients with AF Undergoing PCI: Background

4. WOEST Study Design

5. WOEST - VKA in Patients With AF Undergoing PCI Any Bleeding

6. WOEST - VKA in Patients With AF Undergoing PCI Efficacy

7. PIONEER AF-PCI Study Design

8. PIONEER AF-PCI: Outcomes

9. PIONEER AF-PCI MACE (All Participants)

10. PIONEER AF-PCI Dosing Strategies

11. PIONEER AF-PCI Post-Hoc Analysis: All Cause Mortality and Recurrent Hospitalization

12. RE-DUAL PCI Study Design

13. RE-DUAL PCI Primary Endpoint - Bleeding

14. RE-DUAL PCI Individual Thromboembolic Endpoints

15. AUGUSTUS Study Design

16. AUGUSTUS: Primary Endpoint - Bleeding

17. AUGUSTUS: Secondary Endpoints

18. ENTRUST-AF PCI: Study Design

19. ENTRUST-AF PCI: Primary Endpoint - Bleeding

20. ENTRUST-AF PCI: Landmark Analysis for Primary Endpoint After Day 14

21. ENTRUST-AF PCI: Additional Bleeding Outcomes

22. ENTRUST-AF PCI: Main Efficacy Outcome (ITT Analysis)

23. Meta-Analysis of 4 NOAC trials in AF + PCI

24. Patients with AF Undergoing PCI: Meta-Analysis – NOACs vs VKA

25. ENTRUST-AF PCI: Main Efficacy Endpoint

26. Clinical Considerations…

27. What the Experts Say…

28. Asian Perspective

29. Recommendations for OAC and Antiplatelet Therapy in AF Undergoing PCI

30. 2019 ESC Guidelines for Chronic Coronary Syndromes

31. Abbreviations

32. Abbreviations (cont)